Novavax, Inc. (NVAX)
8.855
-0.08
(-0.95%)
USD |
NASDAQ |
Aug 24, 16:00
8.86
0.00 (0.00%)
After-Hours: 20:00
Novavax PE Ratio
PE Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PE Ratio Data
| Date | Value |
|---|---|
| March 30, 2026 | 3.377 |
| March 27, 2026 | 3.528 |
| March 26, 2026 | 3.736 |
| March 25, 2026 | 3.899 |
| March 24, 2026 | 3.866 |
| March 23, 2026 | 4.058 |
| March 20, 2026 | 4.016 |
| March 19, 2026 | 4.066 |
| March 18, 2026 | 4.179 |
| March 17, 2026 | 4.442 |
| March 16, 2026 | 4.208 |
| March 13, 2026 | 4.273 |
| March 12, 2026 | 4.300 |
| March 11, 2026 | 4.509 |
| March 10, 2026 | 4.463 |
| March 09, 2026 | 4.404 |
| March 06, 2026 | 4.166 |
| March 05, 2026 | 4.170 |
| March 04, 2026 | 4.129 |
| March 03, 2026 | 3.962 |
| March 02, 2026 | 4.221 |
| February 27, 2026 | 4.233 |
| February 26, 2026 | 4.672 |
| February 25, 2026 | 3.978 |
| February 24, 2026 | 3.949 |
| Date | Value |
|---|---|
| February 23, 2026 | 3.908 |
| February 20, 2026 | 3.841 |
| February 19, 2026 | 3.851 |
| February 18, 2026 | 3.628 |
| February 17, 2026 | 3.611 |
| February 13, 2026 | 3.632 |
| February 12, 2026 | 3.515 |
| February 11, 2026 | 3.745 |
| February 10, 2026 | 3.653 |
| February 09, 2026 | 3.632 |
| February 06, 2026 | 3.444 |
| February 05, 2026 | 3.286 |
| February 04, 2026 | 3.452 |
| February 03, 2026 | 3.494 |
| February 02, 2026 | 3.628 |
| January 30, 2026 | 3.692 |
| January 29, 2026 | 3.941 |
| January 28, 2026 | 3.853 |
| January 27, 2026 | 4.100 |
| January 26, 2026 | 4.020 |
| January 23, 2026 | 3.828 |
| January 22, 2026 | 4.070 |
| January 21, 2026 | 4.133 |
| January 20, 2026 | 3.423 |
| January 16, 2026 | 3.344 |
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PE Ratio Benchmarks
| Moderna, Inc. | -- |
| Merck & Co., Inc. | 120.47 |
| Pfizer Inc. | 37.05 |
| Recursion Pharmaceuticals, Inc. | -- |
| Agenus, Inc. | 2.893 |
PE Ratio Related Metrics
| PS Ratio | 3.506 |
| Price | 8.855 |
| Earnings Yield | -17.20% |
| Market Cap | 1.459B |